The FDA has approved a new flu shot that uses mRNA technology. This vaccine, called mFlusiva, is made by Moderna and has been approved for adults 50 to 65 and those 65 and older. The approval is conditional on Moderna running an additional clinical trial in the older age group.

mFlusiva was found to be more effective than a standard flu shot in a late-stage trial. Further details about the vaccine and its approval are available from the FDA and Moderna. This development may impact the availability of flu vaccines in the future, but for now, specifics about local distribution and access are not provided.